Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. McClay, K. Albright, J. Jones, R. Christen, S. Howell (1993)
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.Cancer research, 53 7
E. McClay, J. Jones, P. Winski, K. Albright, R. Christen, S. Howell (1996)
Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.Cancer research, 56 17
T. Wasserman, M. Slavik, S. Carter (1974)
Methyl-CCNU inclinical cancer therapy.Cancer treatment reviews, 1 4
M. al-Sarraf, W. Fletcher, N. Oishi, R. Pugh, Hewlett Js, L. Balducci, J. Mccracken, F. Padilla (1982)
Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.Cancer treatment reports, 66 1
N. Bleehen, E. Newlands, S. Lee, N. Thatcher, P. Selby, A. Calvert, G. Rustin, M. Brampton, M. Stevens (1995)
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 4
L. Feun, R. Gonzalez, N. Savaraj, J. Hanlon, M. Collier, W. Robinson, N. Clendeninn (1991)
Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 3
J. Quagliana, R. Stephens, L. Baker, J. Costanzi (1984)
Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2 4
P. Branch, G. Aquilina, M. Bignami, P. Karran (1993)
Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damageNature, 362
A. Bedikian, G. Weiss, S. Legha, H. Burris, J. Eckardt, J. Jenkins, O. Eton, A. Buzaid, L. Smetzer, D. Hoff (1995)
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
Daniel Fink, S. Nebel, Stefan Aebi, Hua Zheng, Bruno Cenni, Alissar Nehmé, R. Christen, Stephen Howell (1996)
The role of DNA mismatch repair in platinum drug resistance.Cancer research, 56 21
U. Ringborg, C. Rudenstam, J. Hansson, L. Hafström, B. Stenstam, H. Strander (1989)
Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II studyMedical Oncology and Tumor Pharmacotherapy, 6
J. Rusthoven, I. Quirt, N Iscoe, P McCulloch, K James, R Lohmann, J. Jensen, S. Burdette-Radoux, A Bodurtha, H Silver, S. Verma, G Armitage, B. Zee, K. Bennett (1996)
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 7
Evans Lm, Casper Es, R. Rosenbluth (1987)
Phase II trial of carboplatin in advanced malignant melanoma.Cancer treatment reports, 71 2
E. Schoultz, L. Hansson, E. Djureen, Johan Hansson, R. Kärnell, Bo Nilsson, T. Stigbrand, U. Ringborg (1996)
Prognostic value of serum analyses of S‐100β protein in malignant melanomaMelanoma Research, 6
Siow Lee, G. Margison, Ashley Woodcock, N. Thatcher (1993)
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.British Journal of Cancer, 67
Steven Rosenberg, M. Lotze, James Yang, PAUL Aebersold, W. Linehan, C. Seipp, D. White (1989)
Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 210
G. Cocconi, Mariangela Bella, F. Calabresi, M. Tonato, R. Canaletti, Corrado Boni, F. Buzzi, G. Ceci, E. Corgna, Paolo Costa, R. Lottici, Franco Papadia, M. Sofra, M. Bacchi (1992)
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.The New England journal of medicine, 327 8
S. Prete, L. Maurer, J. O'Donnell, R. Forcier, LeMarbre Pj (1984)
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.Cancer treatment reports, 68 11
D. Glover, J. Glick, C. Weiler (1988)
High dose cisplatinurn (DDP) and WR-2721 in metastatic melanomaProc. Am. Soc. Clin. Oncol., 7
J. Schiller, Marilyn Pugh, J. Kirkwood, D. Karp, M. Larson, E. Borden (1996)
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 1
É. Antoine, O. Rixe, É. Vuillemin, A. Benhammouda, C. Borel, G. Ghironzi, E. Mularoni, C. Franks, G. Auclerc, C. Soubrane, P. Banzet, M. Weil, D. Khayat (1995)
A Phase II Study of Tamoxifen Combined with Cisplatin‐Interleukin 2 and Alpha‐Interferon in Metastatic MelanomaAmerican Journal of Clinical Oncology, 18
H. Bailey, R. Mulcahy, K. Tutsch, R. Arzoomanian, D. Alberti, M. Tombes, G. Wilding, M. Pomplun, D. Spriggs (1994)
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 1
P. Philip, V. Souliotis, A. Harris, A. Salisbury, A. Tates, K. Mitchell, J. Delft, T. Ganesan, S. Kyrtopoulos (1996)
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 2
S. Rosenberg, M. Lotze, J. Yang, S. Topalian, A. Chang, D. Schwartzentruber, P. Aebersold, S. Leitman, W. Linehan, C. Seipp, D. White, S. Steinberg (1993)
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.Journal of the National Cancer Institute, 85 8
H. Seigler, Virgil Lucas, N. Pickett, A. Huang (1980)
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanomaCancer, 46
A.I. Einzig, L.M. Schlichter, S. Wadler (1994)
Phase II trial of taxotere (RP 56976) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapyProc. Am. Soc. Clin. Oncol., 13
J.J. Rusthoven, I.C. Quirt, N.A. Iscoe (1996)
Randomized, double-blind, placebo controled trial comparing theresponse rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanomaJ. Clin. Oncol., 14
M. Marchand, P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, Remain Vanwuck, Y. Humblet, J. Canon, C. Laurent, J. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jäger, F. Brasseur, J. Herman, P. Couiae, T. Boon (1995)
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3International Journal of Cancer, 63
E. McClay, M. Mcclay (1994)
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 3
A.I. Einzig, H. Hochster, P.H. Wiernik (1991)
A Phase II study of taxol in patients with malignant melanomaInvest New Drugs, 9
UC Irvine, Jr Meyskens, Kenneth Kopecky, Charles Taylor, R. Noyes, R. Tuthill, Evan Hersh, Lynn Feun, J. Doroshow, Lawrence Flaherty, V. Sondak (1995)
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.Journal of the National Cancer Institute, 87 22
Bernard Cole, R. Gelber, J. Kirkwood, A. Goldhirsch, Edward Barylak, E. Borden (1996)
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 10
S. Retsas, I. Peat, R. Ashford, M. Coe, J. Maher, A. Drury, I. Hanham, R. Phillips, K. Newton, G. Westbury (1980)
Updated results of vindesine as a single agent in the therapy of advanced malignant melanomaCancer Treatment Reviews, 7
O. Rixe, A. Benhammouda, E. Antoine (1994)
Final results of a prospective multicentric study on 91 metastatic malignant melanoma patients treated by chemo-imunotherapy with cisplatin, interleukin-2 and interferon-aProc. Am. Soc. Clin. Oncol., 13
U. Kleeberg, E. Engel, P. Israels, E. Bröcke, W. Tilgen, C. Kennes, B. Gerard, F. Lejeune, M. Glabbeke, M. Lentz (1995)
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group (MCG)Melanoma Research, 5
N.J. Bella, R. Berns, D. Garfield (1984)
Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group studyInvest New Drugs, 2
Alison Stopeck, Evan Hersh, Emmanuel Akporiaye, David Harris, Thomas Grogan, Evan Unger, James Warneke, Samuel Schluter, S. Stahl (1997)
Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
S. Rosenberg, J. Yannelli, J. Yang, S. Topalian, D. Schwartzentruber, J. Weber, D. Parkinson, C. Seipp, J. Einhorn, D. White (1994)
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.Journal of the National Cancer Institute, 86 15
Barbara Smith, P. Selby, J. Southgate, K. Pittman, C. Bradley, G. Blair (1991)
Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reactionThe Lancet, 338
H.H. Bailey, G. Wilding, K.D. Tutsch (1994)
A phase I trial of L-S,R-buthionine sulfoximinegiven as a 24-48-hour continous infusion with iv melphalanProc. Am. Soc. Clin. Oncol., 13
P. O'dwyer, T. Hamilton, R. Young, F. LaCreta, N. Carp, K. Tew, K. Padavic, R. Comis, R. Ozols (1992)
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.Journal of the National Cancer Institute, 84 4
S. Legha, S. Ring, A. Bedikian, C. Plager, O. Eton, A. Buzaid, N. Papadopoulos (1996)
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.Annals of oncology : official journal of the European Society for Medical Oncology, 7 8
T. Wasserman, M. Slavik, S. Carter (1974)
Review of CCNU in clinical cancer therapyCancer Treatment Reviews, 1
C. Falkson, G. Falkson, H. Falkson (1991)
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 8
E. Creagan, R. Dalton, D. Ahmann, S. Jung, R. Morton, R. Langdon, J. Kugler, L Rodrigue (1995)
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 11
Johan Hansson, G. Martenhed, S. Egyházi, E. Tani, A. Platz (1996)
Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction.European journal of cancer, 32A 13
C.I. Falkson, J. Ibrahim, J. Kirkwood (1996)
A randomized phase III trial of dacarbazine (DTTC) versus DTIC+interferon alfa-2b (IFN) versus DTIX+tamoxifen (TMX) versus DTIC+IFN+TMX in metastatic malignant melanoma: an ECOG trialProc. Am. Soc. Clin. Oncol., 15
P. Wiernik, E. Schwartz, A. Einzig, J. Strauman, R. Lipton, J. Dutcher (1987)
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 5 8
U. Ringborg, U. Jungnelius, J. Hansson, H. Strander (1990)
Dacarbazine‐Vindesine‐Cisplatin in Disseminated Malignant Melanoma: A Phase I‐II TrialAmerican Journal of Clinical Oncology, 13
N. Cascinelli (1995)
Evaluation of efficacy of adjuvant rIFNa2a in melanoma patients with regional node metastasesProc. Am. Soc. Clin. Oncol., 14
A. Asea, S. Hermodsson, K. Hellstrand (1996)
Histaminergic Regulation of Natural Killer Cell‐Mediated Clearance of Tumour Cells in MiceScandinavian Journal of Immunology, 43
J. Carmichael, R. Atkinson, K. Calman, R. MacKie, A. Naysmith, J. Smyth (1982)
A multicentre phase II trial of vindesine in malignant melanoma.European journal of cancer & clinical oncology, 18 12
S. Leong (1996)
Immunotherapy of malignant melanoma.The Surgical clinics of North America, 76 6
R. Kärnell, E. Schoultz, L. Hansson, Bo Nilsson, K. Årstrand, Bertil Kågedal (1997)
S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5- methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanomaMelanoma Research, 7
S. Aamdal, B. Gerard, T. Bohman, M. D’Incalci (1992)
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.European journal of cancer, 28 2-3
David Smith, Stanton Gerson, Liii Liu, S. Donnelly, Roger Day, D Trump, J. Kirkwood (1996)
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 7
B. Meisenberg (1996)
High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma.Bone marrow transplantation, 17 6
Anthony Pegg (1990)
Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.Cancer research, 50 19
P. O'Dwyer, Thomas Hamilton, Frank LaCreta, James Gallo, D. Kilpatrick, Theresa Halbherr, James Brennan, M. Bookman, John Hoffman, Robert Young, Robert Comis, Robert Ozols (1996)
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 1
S. Agarwala, J. Kirkwood (1996)
Interferons in melanoma.Current opinion in oncology, 8 2
A.N. Houghton, S. Legha, D.F. Bajorin (1992)
Cutaneous melanoma
J. Kirkwood, M. Strawderman, M. Ernstoff, T. Smith, E. Borden, R. Blum (2023)
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684Journal of Clinical Oncology, 41
H. Joensuu (1991)
Association between chemotherapy response and rate of disease progression in disseminated melanoma.British Journal of Cancer, 63
S. Rosenberg, M. Lotze, J. Yang (1993)
Erratum: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer (J Natl Cancer Inst (1993) 85 (622-632))Journal of the National Cancer Institute, 85
A. Lewis, J. Hayes, C. Wolf (1988)
Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.Carcinogenesis, 9 7
J. Hansson, G. Martenhed, S. Egyházi (1996)
Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reactionEar J Cancer, 32A
D. Khayat, C. Borel, J. Tourani, A. Benhammouda, É. Antoine, O. Rixe, É. Vuillemin, P. Bazex, L. Thill, R. Franks (1993)
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 11
MD Jacquillat, D. Khayat, P. Banzet, MD' WEIL, P. Fumoleau, MD Avril, MD Namer, M. Bonneterre, MD Kerbrat, MD Bonerandi, MDtt Bugat, MD Montcuquet, Cupissol, Mdi Lauvin, MDlTll Vilmer, C. Prache, MD Bizzari (1990)
Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesCancer, 66
K. Hellstrand, P. Naredi, P. Lindner (1994)
Histamine in immunotherapy of advanced melanoma: a pilot studyCancer Immunol. Immunother., 39
F. Brasseur, D. Rimoldi, D. Liénard, B. Lethé, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, A. Vacca, M. Conese, T. Lahaye, G. Degiovanni, R. Deraemaecker, M. Beauduin, X. Sastre, E. Salamon, B. Dréno, E. Jäger, A. Knuth, C. Chevreau, S. Suciu, J. Lachapelle, P. Pouillart, G. Parmiani, F. Lejeune, J. Cerottini, T. Boon, M. Marchand (1995)
Expression of MAGE genes in primary and metastatic cutaneous melanomaInternational Journal of Cancer, 63
E. Krementz, C. Sutherland, Muchmore Jh (1996)
Isolated hyperthermia chemotherapy perfusion for limb melanoma.The Surgical clinics of North America, 76 6
Seppo Pyrhönen, M. Hahka‐Kemppinen, T. Muhonen (1992)
A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 12
S. Legha, S. Ring, N. Papadopoulos, M. Raber, R. Benjamin (1990)
A phase II trial of taxol in metastatic melanomaCancer, 65
K. Suzukake, B. Vistica, D. Vistica (1983)
Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content.Biochemical pharmacology, 32 1
M. Karlsson, U. Jungnelius, S. Aamdal, B. Boeryd, J. Carstensen, B. Kågedal, R. Westberg, S. Wingren (1996)
Correlation of DNA ploidy and S‐phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanomaInternational Journal of Cancer, 65
S. Egyházi, G. Margison, J. Hansson, U. Ringborg (1997)
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.European journal of cancer, 33 1
B. Gerard, Steinar Aamdal, S. Leyvraz, Siow Lee, C. Lucas, J. Bizzari, Maurizio D'Incalci (1993)
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.European journal of cancer, 29A 5
S. Egyházi, G.P. Margison, J. Hansson (1997)
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in melanoma metastasesEar J Cancer, 33
G. Masucci, A. Svensson, M. Hansson, J. Hansson, T. Nakazawa, F. Salazar, M. Petersson, R. Kiessling (1997)
Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).Journal of hematotherapy, 6 3
S. Egyházi, Johan Hansson, Ulrik Ringborg (1995)
O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.British Journal of Cancer, 71
G. Ramírez, W. Wilson, T. Grage, G. Hill (1972)
Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in patients with solid tumors.Cancer chemotherapy reports, 56 6
H. Kassas, J. Kirkwood (1996)
Adjuvant application of interferons.Seminars in oncology, 23 6
D. Hoon, Yuan-Mei Wang, P. Dale, A. Conrad, P. Schmid, D. Garrison, C. Kuo, L. Foshag, A. Nizze, D. Morton (1995)
Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 8
L. Révész, M. Edgren, A. Wainson (1994)
Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.International journal of radiation oncology, biology, physics, 29 2
O. Griffith, A. Meister (1979)
Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine).The Journal of biological chemistry, 254 16
N. Cascinelli (1995)
Evaluation of efficacy of adjuvant rIFN-alfa-2a in melanoma patients with regional nodal metastases (abstract), 14
The present status of medical treatment of malignant melanoma is briefly reviewed, both with regard to adjuvant therapy for individuals with high-risk melanoma and a high probability of harbouring subclinical rnicrometastases, as well as to therapy for establised disseminated (macrometastatic) disease. At present, disseminated, macrometastatic melanoma is incurable in the majority of cases. Single agent chemotherapy has modest effects and results in disease remission in a minority of patients, usually of short duration, Combination chemotherapy, or the combination of chemotherapeutic drugs and cytokines, results in increased response rates and occasionally remissions of prolonged duration. So far, no regimen has demonstrated improved survival compared to single agent therapy in disseminated melanoma. New insights into the mechanisms of resistance to chemotherapeutic drugs may lead to development of predictive tests that can identify individuals with tumors sensitive to a specific agent, as well as to the development of strategies to circumvent drug resistance. It has recently been shown that adjuvant therapy of high-risk melanoma with large doses of interferon-α2b significantly prolongs relapse-free and overall survival, at the price of considerable toxicity. Ongoing studies aim to define the optimum dose and duration of adjuvant interferon therapy. Recent advances in molecular biology and immunology may lead to the development of new treatment modalities, such as improved vaccines and other biologic therapies, which may benefit patients with malignant melanoma.
Medical Oncology – Springer Journals
Published: Nov 14, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.